Почетна › Метастатски карцином › Флорида › Tampa
Клинички испитувања за Метастатски карцином во Tampa, FL
29 студии за Метастатски карцином бараат учесници на локации во и околу Tampa (во радиус од околу 30 милји). Отворете ја студијата за да видите кој може да учествува и како да го контактирате тимот.
Официјален текст на студијата (англиски)
Барате учесници за студија? Истакнете ја на врвот од оваа страница — $99 за 30 дена →
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
Се регрутираФаза 1/2
- Avenzo Therapeutics Recruiting Site, Tampa
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Се регрутираФаза 1
- Moffitt Cancer Center, Tampa
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
Се регрутираФаза 1
- ALX Center 7, Tampa
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Се регрутираФаза 2/3
- Moffitt Cancer Center, Tampa
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
Се регрутираФаза 1
- Moffitt Cancer Center, Tampa
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
Се регрутираФаза 2
- Moffitt Cancer Center, Tampa
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Се регрутираФаза 3
- Florida Cancer Specialists, Tampa
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Се регрутираФаза 1
- Moffitt, Tampa
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Се регрутираФаза 3
- Moffitt Cancer Center, Tampa
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Се регрутираФаза 3
- Moffitt Cancer Center, Richard M. Shulze Family Foundation Outpatient Center, Tampa
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Се регрутираФаза 1/2
- Moffitt Cancer Center and Research Institute, Tampa
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Се регрутираФаза 1/2
- Moffitt Cancer Center, Tampa
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
Се регрутираФаза 1/2
- Avenzo Therapeutics Recruiting Site, Tampa
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
Се регрутираФаза 1
- Moffitt Cancer Center, Tampa
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
Се регрутираФаза 3
- Research Site, Tampa
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
Се регрутираФаза 1
- Investigative Site #128, Tampa
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Се регрутираФаза 1
- Moffitt Cancer Center, Tampa
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
Се регрутираФаза 3
- Moffitt Cancer Center, Tampa
A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors
Се регрутираФаза 1
- Exelixis Clinical Site #8, Tampa
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
Се регрутираФаза 3
- Moffitt Cancer Center, Tampa
Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.
Се регрутираФаза 2
- James A. Haley Veterans Administration Hospital, Tampa
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
Се регрутираФаза 1
- Moffitt Cancer Center, Tampa
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Се регрутираФаза 1
- Lee Moffitt Cancer Center, Tampa
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Се регрутираФаза 1
- Moffitt Cancer Center, Tampa
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Се регрутираФаза 1/2
- Moffitt Cancer Center, Tampa
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
Се регрутираФаза 2/3
- Moffitt Cancer Center, Tampa
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
Се регрутираФаза 3
- Moffitt Cancer Center, Tampa
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Се регрутираНабљудувачка студија
- Massive Bio SYNERGY-AI site, Tampa
IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)
Се регрутираФаза 1
- H. Lee Moffitt Cancer Center and Research Institute, Tampa
Испитувања за Метастатски карцином во други градови
- Houston, TX104 студии
- New York City, NY93 студии
- Nashville, TN70 студии
- Boston, MA63 студии
- Los Angeles, CA57 студии
- St. Louis, MO54 студии
- Arlington, VA53 студии
- Philadelphia, PA46 студии
- Chicago, IL45 студии
- San Antonio, TX44 студии
- Washington, DC43 студии
- Dallas, TX42 студии
Други студии во Tampa
- Рак на бели дробови со не-мали клетки51 студија
- Рак на дојка43 студии
- Рак (сите типови)39 студии
- Колоректален карцином34 студии
- Акутна миелоидна леукемија29 студии
- Рак на бели дробови29 студии
- Карцином на панкреасот26 студии
- Карцином на јајниците21 студија
- Меланом19 студии
- Миелодиспластични синдроми19 студии
- Рак на простата18 студии
- Срцева слабост18 студии
Од ClinicalTrials.gov, податоци преземени 6.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.